These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 22409819)
1. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. Frick M; Dörken B; Lenz G Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819 [TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178 [TBL] [Abstract][Full Text] [Related]
5. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: report of a case in the oral cavity. Jaradat JM; Potluri A; Bilodeau EA Indian J Dent Res; 2013; 24(3):384-6. PubMed ID: 24025890 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma]. Maruyama D Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242 [No Abstract] [Full Text] [Related]
7. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma]. Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125 [TBL] [Abstract][Full Text] [Related]
8. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537 [TBL] [Abstract][Full Text] [Related]
10. Diffuse large B cell lymphoma: how can we cure more patients in 2012? Moskowitz C Best Pract Res Clin Haematol; 2012 Mar; 25(1):41-7. PubMed ID: 22409822 [TBL] [Abstract][Full Text] [Related]
11. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Fabbri A; Gozzetti A; Rigacci L Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541 [No Abstract] [Full Text] [Related]
13. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432 [TBL] [Abstract][Full Text] [Related]
14. Front-line management of diffuse large B cell lymphoma. Cabanillas F Curr Opin Oncol; 2010 Nov; 22(6):642-5. PubMed ID: 20811278 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. Ribera JM; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Navarro JT; Feliu E Br J Haematol; 2012 Jun; 157(5):637-9. PubMed ID: 22313456 [No Abstract] [Full Text] [Related]
16. Molecular outcome prediction in diffuse large-B-cell lymphoma. Alizadeh AA; Gentles AJ; Lossos IS; Levy R N Engl J Med; 2009 Jun; 360(26):2794-5. PubMed ID: 19553658 [No Abstract] [Full Text] [Related]
17. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Testoni M; Kwee I; Greiner TC; Montes-Moreno S; Vose J; Chan WC; Chiappella A; Baldini L; Ferreri AJ; Gaidano G; Mian M; Zucca E; Bertoni F Br J Haematol; 2011 Oct; 155(2):274-7. PubMed ID: 21488860 [No Abstract] [Full Text] [Related]
18. Improving outcomes for patients with diffuse large B-cell lymphoma. Flowers CR; Sinha R; Vose JM CA Cancer J Clin; 2010; 60(6):393-408. PubMed ID: 21030533 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Reiter A; Klapper W Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]